Clinical trials: Disorder, Mood
Nicotine Dependence, Major Depressive Disorder
Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers
Persons who struggle with depression smoke at high rates and experience low quit rates in treatment. The best way to improve cessation treatment for this underserved population remains unknown.
- Trial name
- NCT02378714
- Testing
- Varenicline, BASC, Standard treatment
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Northwestern University
Major Depressive Disorder
PET Biomarkers in Treatment Resistant Depression
The primary objectives of the study are to test whether brain Mono Amine Oxidase-A (MAO-A) levels are elevated in patients with treatment-resistant major depression, and to explore whether MAO-A brain levels predict treatment…
- Trial name
- NCT01031810
- Testing
- tranylcypromine
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)
Study Comparing Discontinuation Symptoms in subjects with Major Depressive Disorder treated for 24 Weeks with Open-label 50 mg Desvenlafaxine Succinate Sustained-Release Formulation (DVS SR)
- Trial name
- NCT01056289
- Testing
- Desvenlafaxine Succinate Sustained-Release Formulation 50 mg, Desvenlafaxine Succinate Sustained-Release Formulation 25 mg
- Volunteers
- 480 people
- Sponsor
- Pfizer
Bipolar Disorder, Depression
A Trial of SAMe for Treatment-Resistant Bipolar Depression
S-adenosyl-L-methionine (SAMe) is a dietary supplement with antidepressant properties. SAMe's mechanism of action remains unclear, but it appears to be distinct from that of conventional antidepressants.
- Conditions
- Bipolar Disorder, Depression, Bipolar Depression
- Trial name
- NCT00762268
- Testing
- SAMe
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mclean Hospital
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD
- Trial name
- NCT01715805
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 85 sites in United States, Puerto Rico
- Volunteers
- 1,022 people
- Sponsor
- Forest Laboratories
Bipolar Disorder, Schizo Affective Disorder
Causal Lesion Network Guided Treatment of Bipolar Mania With Transcranial Electrical Stimulation
Mania is a core symptom of bipolar disorder involving periods of euphoria. Decreased inhibitory control, increased risk-taking behaviors, and aberrant reward processing are some of the more recognized symptoms of bipolar disorder…
- Trial name
- NCT05445466
- Testing
- High-Definition Transcranial Electrical-Current Stimulation, High-Definition Transcranial Alternate-Current Stimulation, High-Definition Personalized Beta-Gamma Electrical Stimulation
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Beth Israel Deaconess Medical Center
Major Depressive Disorder, Anxiety
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
The purpose of this study is to investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in subjects with major depressive disorder and anxiety symptoms, who are experiencing an inadequate…
- Trial name
- NCT02013531
- Testing
- Brexpiprazole
- Where
- 21 sites in United States
- Volunteers
- 37 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophreniform Disorder, Schizoaffective Disorder
Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder.
- Conditions
- Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major
- Trial name
- NCT00421954
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Seasonal Affective Disorder
30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder
The primary objective of this study is to evaluate the effect of light therapy using a narrow 467nm light compared to a 580nm light in subjects with Seasonal Affective Disorder (SAD).
- Trial name
- SAD (NCT01462305)
- Testing
- goLITE, Control
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Philips Respironics
Major Depressive Disorder
A Study of Brexpiprazole in Patients With Major Depressive Disorder
The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of brexipiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy…
- Trial name
- NCT03697603
- Testing
- Brexpiprazole
- Where
- Japan
- Volunteers
- 740 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Bipolar Disorder
Cost- Effectiveness and Quality of Life Assessment in Mood Disorder
To evaluate the effectiveness of three systematic interventions for Bipolar Disorder (BD) mixed episodes using medications available in the Brazilian Public Healthcare System (SUS), and assessment of the quality of life of these…
- Trial name
- NCT02870283
- Testing
- Lithium, Valproic Acid, Carbamazepine
- Volunteers
- 107 people
- Sponsor
- Federal University of Rio Grande do Sul
Cigarette Smoking, Drug Use
Behavioral Intervention for Low Income Depressed Smokers in Drug Treatment
The objective of the proposed project is to develop a novel, behavioral approach to smoking cessation that can be integrated with residential drug use treatment for low income substance using smokers with elevated depressive…
- Trial name
- BA-DAS (NCT01372254)
- Testing
- Standard Treatment, BAD-AS, Transdermal Nicotine Patch
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- University of Maryland, College Park
Major Depressive Disorder
Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder
This proposed study sets out to examine the antidepressant effects of tocilizumab among patients with treatment-refractory major depression.
- Trial name
- NCT02660528
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Brigham and Women's Hospital
Major Depressive Disorder
ECT Pulse Amplitude and Medial Temporal Lobe Engagement
Electroconvulsive therapy (ECT) remains the gold-standard treatment for patients with depressive episodes. During a typical four-week ECT series, most depressive episodes will respond to treatment and people will improve their…
- Trial name
- NCT02999269
- Testing
- MECTA Spectrum 5000Q Amplitude
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of New Mexico
Diabetes, Asthma
Integrated Care (IC) Models for Patient-Centered Outcomes
Multiple chronic conditions (MCC) are widely recognized as the U.S. public health challenge of the 21st century. These physical and behavioral health conditions take a large toll on those living with chronic diseases, including…
- Conditions
- Diabetes, Asthma, Chronic Obstructive Pulmonary Disease, Hypertension
- Trial name
- IC (NCT03451630)
- Testing
- High-Touch, High-Tech, Optimal Discharge Planning
- Where
- United States
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
Study of Repetitive Transcranial Magnetic Stimulation (rTMS) in Depressed Teens
This research study aims to test the safety and effectiveness of repetitive transcranial magnetic stimulation (rTMS) on teens with depression.
- Trial name
- NCT01502033
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Paul E. Croarkin
Major Depression, Cancer
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions…
- Conditions
- Major Depression, Cancer, Diabetes, Cardiovascular Diseases
- Trial name
- NCT01803711
- Testing
- Desvenlafaxine, Omega 3 Fatty acids
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- UConn Health
Major Depressive Disorder
6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
This is a 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder.
- Trial name
- NCT01145755
- Testing
- AZD2066, Duloxetine
- Where
- 13 sites in United States
- Volunteers
- 131 people
- Sponsor
- AstraZeneca
Insomnia, Bipolar Disorder
Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder
The purpose of this study is to evaluate the efficacy of suvorexant, added to existing medications, for treatment-resistant insomnia in individuals with bipolar disorder.
- Trial name
- NCT02527564
- Testing
- Suvorexant
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Stanford University
Depressive Disorder
Depression Attention for Women Now (The DAWN Study)
Major depressive disorder (MDD) is a common disabling illness that disproportionately affects women, with prevalence rates two times those of men.
- Trial name
- DAWN (NCT01096316)
- Testing
- Depression Care Management
- Where
- 2 sites in United States
- Volunteers
- 205 people
- Sponsor
- University of Washington